Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis

Immune-related cutaneous adverse events (irCAEs) in patients treated with programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be associated with better clinical outcomes. However, the extent to which these results can be extrapolated to all tumour types remains u...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fangmin, Zhu, Junjing, Yu, Rui, Shao, Tianyu, Chen, Shuyi, Zhang, Gaochenxi, Shu, Qijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681870/
https://www.ncbi.nlm.nih.gov/pubmed/36414662
http://dx.doi.org/10.1038/s41598-022-24286-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681870/
https://www.ncbi.nlm.nih.gov/pubmed/36414662
http://dx.doi.org/10.1038/s41598-022-24286-3

Ejemplares similares